Corporate Profile

We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.

Our lead product candidate is an inhaled galectin-3 modulator, GB0139, currently in a Phase 2b study for the treatment of idiopathic pulmonary fibrosis. Our pipeline also includes GB1211, a selective oral galectin-3 inhibitor that we are developing for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that we plan to develop for the treatment of myelofibrosis. We plan to further expand the development of GB211 into other indications, including cancer .

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

23 Nov '20
Has extensive experience in pharma and biotech in U.S., Europe and globally Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc.
28 Oct '20
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related
25 Sep '20
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Boston, MA/Copenhagen, Denmark, September 25, 2020 –  Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and

Upcoming Events

More events are coming soon.
View All Events